Zuranolone in Major Depressive Disorder

Anita H. Clayton, MD, shares insights on original research published in The Journal of Clinical Psychiatry, “Zuranolone in Major Depressive Disorder: Results From MOUNTAIN—A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.” She describes how, beginning with day three of treatment, this phase 3 randomized controlled trial found significant improvement in depressive symptoms with zuranolone. As Dr Clayton explains, this neuroactive steroid GABA-A receptor positive allosteric modulator demonstrated rapid antidepressant response to a short, 14-day course of treatment, at 30 mg/day, with improvements in functioning and quality of life. With lower incidence of chronic adverse effects like weight gain and suicidal ideation or behavior, zuranolone continues to be evaluated as an oral, rapid-onset, time-limited therapy for major depressive disorder and postpartum depression.

Read the full study at Psychiatrist.com: https://bit.ly/44TkxKX
…..
Presented by The Journal of Clinical Psychiatry
Anita H. Clayton, MD, is affiliated with the University of Virginia School of Medicine, Charlottesville, Virginia.
@psychiatristcns

Видео Zuranolone in Major Depressive Disorder канала Psychiatrist-CNS